Retatrutide Nasal Spray

Buy Retatrutide Nasal Spray Online

Retatrutide is a once-weekly investigational peptide designed to activate three metabolic hormone receptors: GIP, GLP-1, and glucagon. It has been extensively studied in clinical trials for obesity and metabolic disease.

Product Information

Retatrutide combines three complementary receptor activities within a single molecule. GLP-1 and GIP signaling can influence appetite, glucose regulation, and insulin secretion, while glucagon signaling can increase energy expenditure and influence hepatic metabolism.

How It Works

Retatrutide activates the GIP, GLP-1, and glucagon receptors. This triple-agonist activity is intended to combine appetite and glucose-regulatory effects with glucagon-mediated metabolic activity.

POTENTIAL BENEFITS

1. Weight-Loss Research

In a phase 2 randomized trial involving adults with overweight or obesity, retatrutide produced substantial body-weight reductions over 48 weeks. The study established significant dose-dependent weight-loss signals worthy of continued clinical investigation.

2. Metabolic Research

Retatrutide has been studied for effects on body weight, glucose regulation, insulin sensitivity, and other metabolic markers. Its multi-receptor mechanism makes it distinct from single- and dual-agonist approaches.

3. Appetite-Regulation Research

GLP-1 and GIP receptor activity can influence appetite and food intake, while glucagon activity contributes to energy metabolism. Retatrutide therefore provides a research model for investigating multiple pathways controlling energy balance.

4. Triple-Agonist Research

The defining feature of retatrutide is its simultaneous activation of three hormone receptors. This provides an important platform for studying whether coordinated GIP, GLP-1, and glucagon signaling can produce greater metabolic effects than single-pathway activation.

Dosage

The phase 2 obesity trial studied once-weekly retatrutide doses ranging from 1 mg to 12 mg, using different dose-escalation schedules. These were clinical-trial protocols, not an established general-use dosing regimen. Gastrointestinal adverse events were among the most common treatment-emergent effects. (pubmed.ncbi.nlm.nih.gov)

Side Effects

The phase 2 study reported gastrointestinal adverse events, particularly nausea, diarrhea, and vomiting. Heart-rate increases were also observed. The ongoing clinical development program continues to evaluate longer-term safety and efficacy.

References

1. Jastreboff AM, et al. *Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.* N Engl J Med. 2023;389:514-526.
2. Retatrutide Phase 2 Trial — New England Journal of Medicine.
3. Retatrutide and metabolic disease clinical-trial research.

Note: BehemothLabz does not sell this product. Purchase links on this page may direct to third-party suppliers through affiliate links.

Please click here to see how purchases actually work on this site.